Open access
Open access
Powered by Google Translator Translator

Breast Surgery

SR | Partial breast irradiation for breast cancer

3 Feb, 2023 | 14:06h | UTC

Partial Breast Irradiation for Breast Cancer – Agency for Healthcare Research and Quality

 


SR | Immediate breast reconstruction uptake in older women with primary breast cancer

1 Feb, 2023 | 13:04h | UTC

Immediate breast reconstruction uptake in older women with primary breast cancer: systematic review – British Journal of Surgery

 


SR | Present and future of machine learning in breast surgery

1 Feb, 2023 | 13:03h | UTC

Present and future of machine learning in breast surgery: systematic review – British Journal of Surgery

 

Commentary on Twitter

 


Perspective | Endocrine treatment for 5 years or radiation for 5 days for patients with early breast cancer older than 65 years

26 Jan, 2023 | 12:04h | UTC

Endocrine Treatment for 5 Years or Radiation for 5 Days for Patients With Early Breast Cancer Older Than 65 Years: Can We Do It Right? – Journal of Clinical Oncology

 

Commentary from the author on Twitter

 


RCT | Breast-cancer–related lymphedema after reverse lymphatic mapping and selective axillary dissection vs. standard surgical treatment of axilla

24 Jan, 2023 | 14:15h | UTC

Occurrence of breast-cancer–related lymphedema after reverse lymphatic mapping and selective axillary dissection versus standard surgical treatment of axilla: A two-arm randomized clinical trial – Cancer

 

Commentary on Twitter

 


Cohort Study | Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2

13 Jan, 2023 | 13:14h | UTC

Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 – Journal of Clinical Oncology

Commentary: Incidence of Contralateral Breast Cancers Among Pathogenic Variant Carriers Could Guide Management Decisions – ASCO Daily News

 


Post-trial follow-up | Radiotherapy vs. surgery of the axilla after a positive sentinel node in breast cancer.

14 Dec, 2022 | 14:42h | UTC

Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: ART Preferred Over ALND in Sentinel Node-Positive Early Breast Cancer – Cancer Therapy Advisor

 


Post-trial follow-up | Long-term outcomes of adjuvant denosumab in breast cancer.

22 Nov, 2022 | 13:14h | UTC

Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer – NEJM Evidence 

Original Study: Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial – The Lancet (link to abstract – $ for full-text) 

 


Cohort Study | Use of breast cancer risk factors may identify risk-adapted starting age of screening.

18 Nov, 2022 | 13:16h | UTC

Use of Breast Cancer Risk Factors to Identify Risk-Adapted Starting Age of Screening in China – JAMA Network Open

Invited Commentary: Risk-Based Approaches to Breast Cancer Screening in China – JAMA Network Open

 

Commentary on Twitter

https://twitter.com/JAMANetworkOpen/status/1590766235989708801

 


Phase 2 RCT | Non-hormonal drug reduces vasomotor symptoms in women taking oral adjuvant endocrine therapy after breast cancer.

15 Nov, 2022 | 12:58h | UTC

Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial – The Lancet

Commentary: Non-hormonal therapy reduces hot flashes and night sweats in women who have been diagnosed with breast cancer – Monash University 

 


RCT | Comparison of acupuncture vs. sham acupuncture in the treatment of aromatase inhibitor–related joint pain.

15 Nov, 2022 | 12:47h | UTC

Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor–Related Joint Pain: A Randomized Clinical Trial – JAMA Network Open

Commentary: Aromatase inhibitors and acupuncture in breast cancer: Spinning a negative study, four years later – Science-based Medicine

 

Commentary on Twitter

https://twitter.com/JAMANetworkOpen/status/1591113526222913538

 


RCT | Preoperative ultrasound-guided percutaneous cryoneurolysis for the treatment of pain after mastectomy.

10 Nov, 2022 | 13:41h | UTC

Preoperative Ultrasound-guided Percutaneous Cryoneurolysis for the Treatment of Pain after Mastectomy: A Randomized, Participant- and Observer-masked, Sham-controlled Study – Anesthesiology

Infographic: Tip of the Iceberg: The History of Cryoneurolysis – Anesthesiology

 


Single-arm P2 study | Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy.

2 Nov, 2022 | 14:23h | UTC

Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

News Release: Some breast cancer patients with high responses to chemotherapy may not need surgery: Biopsy protocol identifies patients at low risk of recurrence – University of Texas M. D. Anderson Cancer Center

Commentary: Elimination of Surgery Explored for Selected Breast Cancer Patients – HealthDay

 

Commentary on Twitter

 


Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.

31 Oct, 2022 | 13:50h | UTC

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline – Annals of Oncology

 


Nonsurgical options for risk reduction of contralateral breast cancer in BRCA mutation carriers with early breast cancer.

31 Oct, 2022 | 13:41h | UTC

Nonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer – Journal of Clinical Oncology (free for a limited period)

 


Guideline | Reporting of surgically removed lymph nodes for breast tumors.

25 Oct, 2022 | 13:20h | UTC

Reporting of Surgically Removed Lymph Nodes for Breast Tumors: Recommendations From the International Collaboration on Cancer Reporting – Archives of Pathology & Laboratory Medicine

 


Cohort Study | Systemic or vaginal hormone therapy after early breast cancer.

24 Oct, 2022 | 14:00h | UTC

Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study – JNCI: Journal of the National Cancer Institute

News Release: Hormone replacement therapy doesn’t lead to breast cancer reoccurrence – Oxford University Press

Commentaries:

Expert reaction to study looking at menopausal hormone therapy after early-stage breast cancer, and breast cancer recurrence – Science Media Centre

Hormone Replacement Therapy Won’t Raise Recurrence Rate for Breast Cancer Survivors – HealthDay

 


Recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer.

14 Oct, 2022 | 14:12h | UTC

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022 – Breast Care

See also: Advanced Breast Cancer: AGO Recommendations 2022 – Focus on ABC6 Consensus – Geburtshilfe und Frauenheilkunde

 


Cohort Study | Elevated C-reactive protein and subsequent patient-reported cognitive problems in older breast cancer survivors.

14 Oct, 2022 | 14:03h | UTC

Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study – Journal of Clinical Oncology

News Release: Long-term study supports link between inflammation and cognitive problems in older breast cancer survivors – University of California

 


Cohort Study | Association of long-term oncologic prognosis with minimal access breast surgery vs. conventional breast surgery.

13 Oct, 2022 | 13:38h | UTC

Association of Long-term Oncologic Prognosis With Minimal Access Breast Surgery vs Conventional Breast Surgery – JAMA Surgery

 

Commentary on Twitter

 


RCT | Antibiotic prophylaxis vs. no prophylaxis in breast cancer surgery.

3 Oct, 2022 | 13:47h | UTC

Antibiotic prophylaxis in breast cancer surgery (PAUS trial): randomised clinical double-blind parallel-group multicentre superiority trial – British Journal of Surgery (link to abstract – $ for full-text)

 


20-year follow-up of a RCT | Adjuvant Goserelin and Tamoxifen in premenopausal patients with breast cancer.

26 Sep, 2022 | 12:00h | UTC

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial – Journal of Clinical Oncology

News Release: Hormonal breast cancer treatment reduces long-term risk of recurrence – Karolinska Institutet

 

Commentary on Twitter

 


RCT | Outpatient vs. inpatient preinduction cervical ripening using a synthetic osmotic dilator.

26 Sep, 2022 | 11:58h | UTC

Outpatient Compared With Inpatient Preinduction Cervical Ripening Using a Synthetic Osmotic Dilator: A Randomized Clinical Trial – Obstetrics & Gynecology

 


M-A | Margin status and survival outcomes after breast cancer conservation surgery.

23 Sep, 2022 | 13:09h | UTC

Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis – The BMJ

Commentary from the authors: Width of excision margins after breast conserving surgery for invasive breast cancer and distant recurrence and survival – The BMJ

News Release: Experts call for adequate tumour free margins in breast cancer surgery – BMJ Newsroom

 


RCT | Multiple doses of prophylactic intravenous antibiotics are no better than a single dose in implant-based breast reconstruction.

19 Sep, 2022 | 12:48h | UTC

Effectiveness of Single vs Multiple Doses of Prophylactic Intravenous Antibiotics in Implant-Based Breast Reconstruction: A Randomized Clinical Trial – JAMA Network Open

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.